XKRX
464280
, Last price
KRW
Name
TDSPharm Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
808.27
Vol. 1Y
—
Shs. 5Y
121.15%
Rev. 5Y
8.91%
Div Yld LY
—
Div Yld TTM
—
Revenues
27.62b
+0.37%
Net income
4.27b
+14.97%
CFO
3.78b
-3.79%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established on November 11, 2002, TDS Pharm Co. Ltd. is headquartered in Seongnam-si, South Korea, and specializes in the creation and manufacturing of transdermal drug delivery solutions. Their offerings include items such as cataplasma, plasta, fucidin band, and various prescription pharmaceuticals.
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT |